Amneal Pharmaceuticals, Inc.announced that the U.S. Food and Drug Administration has approved the Company’s Biologics License Applicationfor pegfilgrastim-pbbk, a biosimilar referencing Neulasta. The product will be marketed under the proprietary name FYLNETRA.
- Read more about Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/amneal-achieves-third-us-biosimilar-approval-with-fylnetra
No comments:
Post a Comment